AGM/EGMApr 30, 2026, 05:23 PM
OCUL Annual Meeting June 10; Stock Plan Increase, Positive AXPAXLI Data
AI Summary
Ocular Therapeutix, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026. Key proposals include the election of two Class III directors and an amendment to increase shares under the 2021 Stock Incentive Plan by 10,000,000. The company also highlighted a transformative 2025, with significant progress in advancing AXPAXLI Phase 3 programs for wet AMD and diabetic retinal disease, and the announcement of positive superiority data from the SOL-1 Phase 3 trial in February 2026. A successful $475 million fundraising in Fall 2025 extended the cash runway into 2028.
Key Highlights
- Annual Meeting of Stockholders scheduled for June 10, 2026, to be held virtually.
- Proposal to amend 2021 Stock Incentive Plan to increase shares by 10,000,000.
- Positive superiority data from AXPAXLI SOL-1 Phase 3 trial in wet AMD announced Feb 2026.
- Completed enrollment and randomization in AXPAXLI SOL-R Phase 3 trial for wet AMD.
- Obtained FDA Special Protocol Assessment (SPA) for diabetic retinal disease pivotal trial.
- Raised $475 million in gross proceeds from an underwritten offering in Fall 2025.
- Anticipated cash inflows from DEXTENZA expected to fund operations into 2028.
Price Impact
More from OCUL